Related references
Note: Only part of the references are listed.Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Eμ-TCL1 mice
Bola S. Hanna et al.
HAEMATOLOGICA (2021)
Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients
Fuli Fan et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
Maissa Mhibik et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition
Albert Liclican et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2020)
Noncatalytic Bruton's tyrosine kinase activates PLC?2 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells
Martin Wist et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
Philipp M. Roessner et al.
LEUKEMIA (2020)
Treatment of Chronic Lymphocytic Leukemia
Jan A. Burger
NEW ENGLAND JOURNAL OF MEDICINE (2020)
LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study
Anthony R. Mato et al.
BLOOD (2020)
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
Loretta J. Nastoupil et al.
LANCET HAEMATOLOGY (2019)
IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia
Annika Scheffold et al.
BLOOD (2019)
Ibrutinib and Venetoclax for First-Line Treatment of CLL
Nitin Jain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment
Michael Hallek
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations
Eliana B. Gomez et al.
BLOOD (2019)
LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL
Aishath S. Naeem et al.
BLOOD (2019)
PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia
Bola S. Hanna et al.
LEUKEMIA (2019)
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study
Matthew S. Davids et al.
LANCET HAEMATOLOGY (2019)
Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia
Helen M. Parry et al.
FRONTIERS IN IMMUNOLOGY (2019)
Resistance mechanism for ibrutinib in marginal zone lymphoma
Narendranath Epperla et al.
BLOOD ADVANCES (2019)
Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment
Iris de Weerdt et al.
BLOOD ADVANCES (2019)
From Biology to Therapy: The CLL Success Story
Deyan Y. Yosifov et al.
HEMASPHERE (2019)
Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
Susan O'Brien et al.
BLOOD (2018)
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
Sean D. Reiff et al.
CANCER DISCOVERY (2018)
Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies
Elisa ten Hacken et al.
JCI INSIGHT (2018)
Ibrutinib treatment improves T cell number and function in CLL patients
Meixiao Long et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia
Qingsong Yin et al.
JOURNAL OF IMMUNOLOGY (2017)
Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia
J. Deng et al.
LEUKEMIA (2017)
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy
David Miklos et al.
BLOOD (2017)
Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation
Minke E. Binnerts et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Joseph A. Fraietta et al.
BLOOD (2016)
Noninvasive Detection of Ibrutinib Resistance in Non-Hodgkin Lymphoma Using Cell-Free DNA
Florian Scherer et al.
BLOOD (2016)
Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma
Idit Sagiv-Barfi et al.
BLOOD (2015)
Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eμ-TCL1 CLL mouse model
Fabienne McClanahan et al.
BLOOD (2015)
Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy
Martin F. M. de Rooij et al.
BLOOD (2015)
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
Idit Sagiv-Barfi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
Jennifer A. Woyach et al.
BLOOD (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production
John C. Riches et al.
BLOOD (2013)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader et al.
BLOOD (2012)
Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling
Marcus Duehren-von Minden et al.
NATURE (2012)
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD (2011)
B-cell receptor signaling in chronic lymphocytic leukemia
Freda K. Stevenson et al.
BLOOD (2011)
T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse
Amy E. Moran et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin
Charles C. Chu et al.
BLOOD (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies
Anna Lanemo Myhrinder et al.
BLOOD (2008)
Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA
Charles C. Chu et al.
BLOOD (2008)
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members
Michael Certo et al.
CANCER CELL (2006)
Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity
M Hervé et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Share Paper
